600521 华海药业
交易中 05-22 13:55:42
资讯
新帖
简况
华海药业(600521)披露关于募集资金账户注销的公告,5月21日股价上涨2.22%
证券之星 · 05-21 17:47
华海药业(600521)披露关于募集资金账户注销的公告,5月21日股价上涨2.22%
每周股票复盘:华海药业(600521)拟每股派息0.1元
证券之星 · 05-17
每周股票复盘:华海药业(600521)拟每股派息0.1元
华海药业(600521)披露2025年年度股东会资料,5月14日股价下跌2.24%
证券之星 · 05-14
华海药业(600521)披露2025年年度股东会资料,5月14日股价下跌2.24%
5月11日华海药业涨6.14%,兴业医疗保健混合A基金重仓该股
证券之星 · 05-11
5月11日华海药业涨6.14%,兴业医疗保健混合A基金重仓该股
华海药业公布国际专利申请:“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”
证券之星 · 05-02
华海药业公布国际专利申请:“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”
华海药业(600521)2026年一季报简析:净利润同比增长35.9%
证券之星 · 05-01
华海药业(600521)2026年一季报简析:净利润同比增长35.9%
华海药业(600521)披露变更部分募投项目并将节余募集资金用于新建项目及永久补充流动资金的公告,4月30日股价上涨1.81%
证券之星 · 04-30
华海药业(600521)披露变更部分募投项目并将节余募集资金用于新建项目及永久补充流动资金的公告,4月30日股价上涨1.81%
图解华海药业一季报:第一季度单季净利润同比增长35.90%
证券之星 · 04-30
图解华海药业一季报:第一季度单季净利润同比增长35.90%
每周股票复盘:华海药业(600521)将举办投资者开放日活动
证券之星 · 04-26
每周股票复盘:华海药业(600521)将举办投资者开放日活动
华海药业(600521)披露投资者开放日活动公告,4月21日股价下跌1.1%
证券之星 · 04-21
华海药业(600521)披露投资者开放日活动公告,4月21日股价下跌1.1%
华海药业(600521)披露董事会提议向下修正“华海转债”转股价格,4月20日股价下跌2.67%
证券之星 · 04-20
华海药业(600521)披露董事会提议向下修正“华海转债”转股价格,4月20日股价下跌2.67%
每周股票复盘:华海药业(600521)Q1净利预盈3.87亿至4.4亿
证券之星 · 04-19
每周股票复盘:华海药业(600521)Q1净利预盈3.87亿至4.4亿
华海药业(600521.SH)发预增,预计一季度归母净利润同比增长约30%到48%
智通财经 · 04-14
华海药业(600521.SH)发预增,预计一季度归母净利润同比增长约30%到48%
华海药业(600521)披露获得美沙拉秦肠溶片药品注册证书,4月7日股价下跌0.13%
证券之星 · 04-07
华海药业(600521)披露获得美沙拉秦肠溶片药品注册证书,4月7日股价下跌0.13%
每周股票复盘:华海药业(600521)华海转债累计转股6,359股
证券之星 · 04-05
每周股票复盘:华海药业(600521)华海转债累计转股6,359股
华海药业最新公告:美沙拉秦肠溶片获药品注册证书
证券之星 · 04-03
华海药业最新公告:美沙拉秦肠溶片获药品注册证书
华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,4月2日股价下跌0.54%
证券之星 · 04-02
华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,4月2日股价下跌0.54%
每周股票复盘:华海药业(600521)华奥泰获Almirall最高3.4亿美元合作款
证券之星 · 03-29
每周股票复盘:华海药业(600521)华奥泰获Almirall最高3.4亿美元合作款
华海药业(600521)披露控股子公司签订合作开发和许可协议,3月27日股价上涨5.89%
证券之星 · 03-27
华海药业(600521)披露控股子公司签订合作开发和许可协议,3月27日股价上涨5.89%
华海药业(600521.SH)子公司华奥泰与ALM达成全球研究合作及许可协议
智通财经 · 03-27
华海药业(600521.SH)子公司华奥泰与ALM达成全球研究合作及许可协议
加载更多
公司概况
公司名称:
浙江华海药业股份有限公司
所属行业:
医药制造业
上市日期:
2003-03-04
主营业务:
浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是厄贝沙坦氢氯噻嗪片、氯沙坦钾片、厄贝沙坦片、利伐沙班片、安立生坦片、缬沙坦氢氯噻嗪片、缬沙坦氨氯地平片、缬沙坦片、福辛普利钠片、盐酸舍曲林片、奥氮平片、盐酸帕罗西汀片、草酸艾司西酞普兰片、盐酸多奈哌齐片、磷酸奥司他韦胶囊、伏立康唑片、依非韦伦片。
发行价格:
15.55
{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":16.47,"timestamp":1779429342000,"preClose":17.02,"halted":0,"volume":31625050,"delay":0,"changeRate":-0.0323,"floatShares":1497000000,"shares":1497000000,"eps":0.2493,"marketStatus":"交易中","change":-0.55,"latestTime":"05-22 13:55:42","open":17.3,"high":17.37,"low":16.34,"amount":525000000,"amplitude":0.0605,"askPrice":16.47,"askSize":494,"bidPrice":16.46,"bidSize":232,"shortable":0,"etf":0,"ttmEps":0.2493,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779433200000},"marketStatusCode":2,"adr":0,"adjPreClose":17.02,"symbolType":"stock","openAndCloseTimeList":[[1779413400000,1779420600000],[1779426000000,1779433200000]],"highLimit":18.72,"lowLimit":15.32,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1497252136,"isCdr":false,"pbRate":2.65,"roa":"--","peRate":66.064982,"roe":"4.19%","epsLYR":0.18,"committee":0.092744,"marketValue":24660000000,"turnoverRate":0.0211,"status":1,"floatMarketCap":24660000000},"requestUrl":"/m/hq/s/600521","defaultTab":"news","newsList":[{"id":"2637986381","title":"华海药业(600521)披露关于募集资金账户注销的公告,5月21日股价上涨2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637986381","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637986381?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:47","pubTimestamp":1779356865,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,华海药业报收于17.02元,较前一交易日上涨2.22%,最新总市值为254.83亿元。该股当日开盘16.61元,最高17.65元,最低16.61元,成交额达11.02亿元,换手率为4.28%。浙江华海药业股份有限公司于2026年5月21日发布《关于募集资金账户注销的公告》。存放于工行临海支行的募集资金专户资金已使用完毕,现对该账户予以注销,相关《募集资金专户四方监管协议》相应终止。本次账户注销后,公司2020年可转债募集资金所有专用账户均已全部注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100032991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600521","BK0028","BK0012","BK0185","BK0201","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636770064","title":"每周股票复盘:华海药业(600521)拟每股派息0.1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636770064","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636770064?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:50","pubTimestamp":1778961022,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,华海药业报收于16.52元,较上周的16.45元上涨0.43%。本周,华海药业5月11日盘中最高价报17.67元。浙江华海药业股份有限公司将于2026年5月21日召开2025年年度股东会,会议采取现场投票与网络投票相结合方式,股权登记日为2026年5月14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","BK0028","BK0012","BK0201","600521","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635659745","title":"华海药业(600521)披露2025年年度股东会资料,5月14日股价下跌2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635659745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635659745?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:15","pubTimestamp":1778768122,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,华海药业报收于16.57元,较前一交易日下跌2.24%,最新总市值为248.09亿元。该股当日开盘17.0元,最高17.02元,最低16.52元,成交额达4.06亿元,换手率为1.63%。公司2025年实现营业收入85.87亿元,净利润2.66亿元,拟每股派发现金红利0.1元(含税)。同时提议变更部分募集资金用途,用于建设年产8000kg索马鲁肽中间体项目并永久补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400042866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0188","BK0012","BK0028","600521","BK0070","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409333","title":"5月11日华海药业涨6.14%,兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409333","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409333?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:24","pubTimestamp":1778487892,"startTime":"0","endTime":"0","summary":"证券之星消息,5月11日华海药业涨6.14%创60日新高,收盘报17.46元,换手率4.75%,成交量71.13万手,成交额12.16亿元。重仓华海药业的公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为21.3。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0028","BK0070","BK0188","BK0201","BK0239","BK0185","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623508","title":"华海药业公布国际专利申请:“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623508?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:59","pubTimestamp":1777672752,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示华海药业(600521)公布了一项国际专利申请,专利名为“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”,专利申请号为PCT/CN2024/126359,国际公布日为2026年4月30日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来华海药业已公布的国际专利申请5个,较去年同期增加了25%。结合公司2025年年报财务数据,2025年公司在研发方面投入了12.29亿元,同比增24.57%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","600521","BK0188","BK0070","BK0239","BK0201","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632667694","title":"华海药业(600521)2026年一季报简析:净利润同比增长35.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632667694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632667694?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:11","pubTimestamp":1777587075,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期华海药业发布2026年一季报。根据财报显示,华海药业净利润同比增长35.9%。截至本报告期末,公司营业总收入23.35亿元,同比下降1.4%,归母净利润4.04亿元,同比上升35.9%。持有华海药业最多的基金为兴业医疗保健混合A,目前规模为2.41亿元,最新净值0.8161,较上一交易日上涨0.54%,近一年上涨23.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100004578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631682589","title":"华海药业(600521)披露变更部分募投项目并将节余募集资金用于新建项目及永久补充流动资金的公告,4月30日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631682589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631682589?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:50","pubTimestamp":1777542650,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,华海药业报收于16.29元,较前一交易日上涨1.81%,最新总市值为243.9亿元。近日,华海药业披露《关于变更部分募投项目并将节余募集资金用于新建项目及永久补充流动资金的公告》。公司拟将原“制剂数字化智能制造建设项目”节余募集资金约14,850万元用于“年产8,000kg索马鲁肽中间体建设项目”及永久补充流动资金。本次变更涉及金额占募集资金净额的25.50%。该事项已通过董事会相关会议审议,尚需股东大会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000057929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0070","BK0239","BK0185","BK0201","600521","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631152813","title":"图解华海药业一季报:第一季度单季净利润同比增长35.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631152813","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631152813?lang=zh_cn&edition=full","pubTime":"2026-04-30 03:14","pubTimestamp":1777490082,"startTime":"0","endTime":"0","summary":"证券之星消息,华海药业2026年一季报显示,一季度公司主营收入23.35亿元,同比下降1.4%;归母净利润4.04亿元,同比上升35.9%;扣非净利润1.36亿元,同比下降52.19%;负债率55.64%,投资收益2.43亿元,财务费用1.04亿元,毛利率57.67%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000009044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630801578","title":"每周股票复盘:华海药业(600521)将举办投资者开放日活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2630801578","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630801578?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:10","pubTimestamp":1777140622,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,华海药业报收于15.72元,较上周的16.88元下跌6.87%。本周,华海药业4月20日盘中最高价报16.82元。华海药业当前最新总市值235.37亿元,在化学制药板块市值排名18/150,在两市A股市值排名905/5200。本周关注点公司公告汇总:华海药业将于2026年5月11日举办投资者开放日活动。公司将介绍发展战略、经营状况及核心业务布局,并听取投资者意见。活动结束后,公司将通过指定信息披露媒体公告活动情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600000715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0201","BK0185","BK0012","BK0070","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603030","title":"华海药业(600521)披露投资者开放日活动公告,4月21日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629603030?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:11","pubTimestamp":1776780678,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘,华海药业报收于16.25元,较前一交易日下跌1.1%,最新总市值为243.3亿元。该股当日开盘16.33元,最高16.56元,最低16.16元,成交额达3.31亿元,换手率为1.36%。近日,浙江华海药业股份有限公司披露《关于举办投资者开放日活动的公告》。公告显示,公司将于2026年5月11日在上海浦东香格里拉大酒店举办投资者开放日活动,活动时间为9:00-16:00,采取现场召开方式。活动结束后,公司将通过指定信息披露媒体公告活动情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100052806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0028","BK0201","600521","BK0012","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628746883","title":"华海药业(600521)披露董事会提议向下修正“华海转债”转股价格,4月20日股价下跌2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628746883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628746883?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:17","pubTimestamp":1776676665,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘,华海药业报收于16.43元,较前一交易日下跌2.67%,最新总市值为246亿元。该股当日开盘16.61元,最高16.82元,最低16.38元,成交额达5.94亿元,换手率为2.41%。浙江华海药业股份有限公司于2026年4月17日召开第九届董事会第十次临时会议,审议通过《关于提议向下修正“华海转债”转股价格的议案》。本次向下修正事项尚需提交公司股东会审议,股东会召开时间将另行通知。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0028","BK0070","BK0188","BK0201","BK0239","BK0185","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628756853","title":"每周股票复盘:华海药业(600521)Q1净利预盈3.87亿至4.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2628756853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628756853?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:10","pubTimestamp":1776532218,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,华海药业报收于16.88元,较上周的16.19元上涨4.26%。本周,华海药业4月17日盘中最高价报17.16元。华海药业发布业绩预告,预计2026年1-3月归属净利润盈利3.87亿元至4.4亿元。华海药业近日即将发布2025年年报,根据4月14日发布的业绩快报,归属净利润盈利2.669亿元,同比减少76.14%。公司公告汇总浙江华海药业股份有限公司于2026年4月17日召开第九届董事会第十次临时会议,审议通过《关于提议向下修正“华海转债”转股价格的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0070","600521","BK0239","BK0201","BK0028","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445038","title":"华海药业(600521.SH)发预增,预计一季度归母净利润同比增长约30%到48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627445038?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:11","pubTimestamp":1776168692,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华海药业 发布2026年一季度业绩预告,预计2026年一季度实现归属于上市公司股东的净利润预计在3.87亿元至4.4亿元,与上年同期相比,将增加约8,960万元到14,260万元,同比增长约30%到48%。报告期内,公司实现归属于上市公司股东的净利润较去年同期大幅增长,主要系公司本期处置子公司华海天衡(上海)药物研究股份有限公司67%股权产生的收益所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华海药业(600521.SH)发预增,预计一季度归母净利润同比增长约30%到48%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625939322","title":"华海药业(600521)披露获得美沙拉秦肠溶片药品注册证书,4月7日股价下跌0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625939322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625939322?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:29","pubTimestamp":1775554157,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘,华海药业报收于15.86元,较前一交易日下跌0.13%,最新总市值为237.46亿元。该股当日开盘15.99元,最高16.19元,最低15.51元,成交额达2.98亿元,换手率为1.25%。浙江华海药业股份有限公司近日收到国家药品监督管理局核准签发的美沙拉秦肠溶片《药品注册证书》,药品批准文号为国药准字H20263759,剂型为片剂,规格0.5g,注册分类为化学药品4类。该药品用于溃疡性结肠炎和克罗恩病急性发作期的治疗。截至目前,公司该项目研发投入约1243万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600521","BK0185","BK0201","BK0012","BK0070","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625615702","title":"每周股票复盘:华海药业(600521)华海转债累计转股6,359股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625615702","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625615702?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:35","pubTimestamp":1775324112,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,华海药业报收于15.88元,较上周的15.82元上涨0.38%。本周关注点公司公告汇总:华海转债累计转股6,359股,占转股前总股本的0.00044%公司公告汇总:美沙拉秦肠溶片获药品注册证书,视同通过一致性评价公司公告汇总浙江华海药业股份有限公司可转换公司债券自2021年5月6日开始转股,截至2026年3月31日,累计有217,000元转为公司股份,合计转股6,359股,占转股前总股本的0.00044%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0028","BK0201","600521","BK0012","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624569396","title":"华海药业最新公告:美沙拉秦肠溶片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624569396","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624569396?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:01","pubTimestamp":1775206879,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司近日收到国家药监局核准签发的美沙拉秦肠溶片《药品注册证书》。该药品规格为0.5g,主要用于溃疡性结肠炎及克罗恩病的治疗。根据米内网数据预测,该产品2025年国内市场规模约7.87亿元。截至目前,公司在该项目上已投入研发费用约1243万元。此次获批可视同通过一致性评价,有助于丰富公司产品线并提升市场竞争力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300032840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0185","BK0188","600521","BK0201","BK0012","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574064","title":"华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,4月2日股价下跌0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574064","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624574064?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:07","pubTimestamp":1775120869,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘,华海药业报收于16.5元,较前一交易日下跌0.54%,最新总市值为247.05亿元。该股当日开盘16.5元,最高16.69元,最低16.36元,成交额达4.93亿元,换手率为2.0%。公司于2026年4月2日发布《浙江华海药业股份有限公司可转换公司债券转股结果暨股份变动公告》。公告显示,华海转债自2021年5月6日开始转股,截至2026年3月31日,累计有217,000元转为公司股份,合计转股6,359股,占转股前总股本的0.00044%。本季度无转股发生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0201","BK0239","BK0185","BK0012","600521","BK0070","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623438705","title":"每周股票复盘:华海药业(600521)华奥泰获Almirall最高3.4亿美元合作款","url":"https://stock-news.laohu8.com/highlight/detail?id=2623438705","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623438705?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:38","pubTimestamp":1774719492,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,华海药业报收于15.82元,较上周的15.3元上涨3.4%。本周关注点公司公告汇总:华奥泰与Almirall签署协议,可获不超过3.4亿美元款项及分级特许权使用费。公司控股子公司上海华奥泰生物药业股份有限公司与Almirall,S.A.签署全球研究合作及许可协议,共同开发新靶点的单克隆抗体候选药物。Almirall将向华奥泰支付总额不超过3.4亿美元的款项及分级特许权使用费。华奥泰拥有在中国境内的开发和商业化权利,Almirall拥有中国以外地区的相关权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","BK0028","BK0012","BK0201","600521","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622382053","title":"华海药业(600521)披露控股子公司签订合作开发和许可协议,3月27日股价上涨5.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622382053","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622382053?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:06","pubTimestamp":1774620381,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,华海药业报收于15.82元,较前一交易日上涨5.89%,最新总市值为236.87亿元。近日,浙江华海药业股份有限公司发布《关于控股子公司签订合作开发和许可协议的公告》。公告显示,公司下属控股子公司上海华奥泰生物药业股份有限公司与Almirall,S.A.签署全球研究合作及许可协议,就一款新靶点单克隆抗体候选药物进行合作开发。协议已于2026年3月26日签署,业经公司董事会审议通过,无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700049216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0185","600521","BK0188","BK0070","BK0239","BK0028","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622460768","title":"华海药业(600521.SH)子公司华奥泰与ALM达成全球研究合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2622460768","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622460768?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:16","pubTimestamp":1774599418,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华海药业(600521.SH)发布公告,公司下属控股子公司上海华奥泰生物药业股份有限公司(以下简称“华奥泰”)与Almirall,S.A.(以下简称“ALM”)达成全球研究合作及许可协议,用于开发具有多种潜在适应症(包括医学皮肤科)的新靶点的单克隆抗体候选药物。根据协议,华奥泰拥有在中国开发和商业化项目和产品的权利,ALM拥有在中国以外的全球开发和商业化项目和产品的权利。利用创新研发平台,华奥泰将开展相关研究,直至获得具有临床概念验证的分子,ALM将向华奥泰支付总额不超过3.4亿美元的首付款、开发和商业化里程碑付款,以及相应的分级特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALM","BK0012","600521","BK0070","BK0188","BK0239","BK0201","BK4168","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779429347348,"stockEarnings":[{"period":"1week","weight":0.0272},{"period":"1month","weight":0.0474},{"period":"3month","weight":0.0834},{"period":"6month","weight":0.0131},{"period":"1year","weight":0.109},{"period":"ytd","weight":0.0029}],"compareEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0012},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2036},{"period":"ytd","weight":0.0273}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"89340人(较上一季度增加8.11%)","perCapita":"16759股","listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥镇汛大路88号","registeredCapital":"149725万元","survey":" 浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是厄贝沙坦氢氯噻嗪片、氯沙坦钾片、厄贝沙坦片、利伐沙班片、安立生坦片、缬沙坦氢氯噻嗪片、缬沙坦氨氯地平片、缬沙坦片、福辛普利钠片、盐酸舍曲林片、奥氮平片、盐酸帕罗西汀片、草酸艾司西酞普兰片、盐酸多奈哌齐片、磷酸奥司他韦胶囊、伏立康唑片、依非韦伦片。","listedPrice":15.55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}